All In Biotech

Drug Trial Radar · NCT00000748

A Randomized, Comparative, Prospective Study of Daily Trimethoprim / Sulfamethoxazole (TMS) and Thrice-Weekly TMS for Prophylaxis Against PCP in HIV-Infected Patients

Last checked: Nov 19, 2026Latest source record: Nov 4, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,500

Actual

Start

Not stated

Primary completion

Not stated

Study completion Nov 1996

Sponsor

Sponsor type
NIH
Collaborators
Glaxo Wellcome
First posted
Aug 31, 2001

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Model
Parallel
Primary purpose
Treatment
Who can join
All sexes, from 13 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To compare the safety and efficacy of two dosage regimens (daily and thrice-weekly) of sulfamethoxazole/trimethoprim (SMX/TMP; TMS) in the prevention of Pneumocystis carinii pneumonia (PCP) in high-risk HIV-infected patients. Previous tests have shown that SMX/TMP given daily is effective in preventing recurrence of PCP and may be effective in preventing PCP in patients who have never developed it. Because SMX/TMP can cause side effects, this study will attempt to determine the safest and most effective dose of this combination.

Conditions

  • Pneumonia, Pneumocystis Carinii
  • HIV Infections

Interventions

  • Sulfamethoxazole-TrimethoprimDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

24 sites in 1 country. Site status is shown where the registry gives one.

  • Community Consortium of San Francisco

    San Francisco, California

  • Stanford Univ School of Medicine

    Stanford, California

  • Denver CPCRA / Denver Public Hlth

    Denver, Colorado

  • Wilmington Hosp / Med Ctr of Delaware

    Wilmington, Delaware

  • Veterans Administration Med Ctr / Regional AIDS Program

    Washington D.C., District of Columbia

  • AIDS Research Consortium of Atlanta

    Atlanta, Georgia

  • AIDS Research Alliance - Chicago

    Chicago, Illinois

  • Louisiana Comm AIDS Rsch Prog / Tulane Univ Med

    New Orleans, Louisiana

  • Baltimore Trials

    Baltimore, Maryland

  • Univ of Maryland at Baltimore

    Baltimore, Maryland

  • Comprehensive AIDS Alliance of Detroit

    Detroit, Michigan

  • Henry Ford Hosp

    Detroit, Michigan

  • Southern New Jersey AIDS Cln Trials / Dept of Med

    Camden, New Jersey

  • North Jersey Community Research Initiative

    Newark, New Jersey

  • Partners Research

    Albuquerque, New Mexico

  • Univ Hosp / HIV - ID Clinic

    Albuquerque, New Mexico

  • Addiction Research and Treatment Corp

    Brooklyn, New York

  • Clinical Directors Network of Region II

    New York, New York

  • Harlem AIDS Treatment Group / Harlem Hosp Ctr

    New York, New York

  • Bronx Lebanon Hosp Ctr

    The Bronx, New York

  • Portland Veterans Adm Med Ctr / Rsch & Education Grp

    Portland, Oregon

  • Philadelphia FIGHT

    Philadelphia, Pennsylvania

  • Richmond AIDS Consortium

    Richmond, Virginia

  • Univ of Washington / Pacific Med Ctr

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.